Bio-Techne Q3 Adj $0.48 Beats $0.45 Estimate, Sales $303.43M Beat $292.19M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bio-Techne (NASDAQ:TECH) reported Q3 adjusted earnings of $0.48 per share, surpassing the $0.45 estimate, and sales of $303.43M, exceeding the $292.19M estimate. This represents a 9.43% decrease in earnings and a 3.16% increase in sales from the same period last year.
May 01, 2024 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Techne's Q3 earnings and sales beat estimates, with a slight decrease in earnings but an increase in sales compared to last year.
Beating both earnings and sales estimates typically has a positive impact on a company's stock price in the short term. The decrease in earnings year-over-year might temper some of the positive momentum, but the overall beat and sales growth are likely to be viewed favorably by investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100